Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of a 24-valent pneumococcal conjugate vaccine in infants and children aged 6 weeks to 71 months
CTR20253387Phase 2Active
- Sponsor
- Ruizhou Biotech
- Start
- Sep 2025
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of Reinovax PCV24 in pneumococcal disease, sponsored by Ruizhou Biotech. Started Sep 2025; status: active.
02
Drugs
Reinovax PCV24
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on CTR20253387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253387.